Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis

American Journal of Drug and Alcohol Abuse

Volumn 40, Issue 1, 2014, Pages 10-15

  Farnia, Vahid ^a   Shakeri, Jalal ^a   Tatari, Faezeh ^a   Juibari, Toraj Ahmadi ^a   Yazdchi, Katayoun ^b   Bajoghli, Hafez ^c   Brand, Serge ^d   Abdoli, Nasrin ^e   Aghaei, Abbas ^a  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF BASEL   (Switzerland)

^e IMAM REZA INTERNATIONAL UNIVERSITY   (Iran)

Author keywords

Amphetamine; Aripiprazole; Psychotic disorders; Risperidone; Scale for Assessment of Negative Symptoms; Scale for Assessment of Positive Symptoms

Indexed keywords

AMPHETAMINE; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; RISPERIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ANHEDONIA; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DELUSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HALLUCINATION; HUMAN; INSOMNIA; MALE; MIDDLE AGED; NEGATIVE SYNDROME; POSITIVE SYNDROME; PSYCHOMETRY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK REDUCTION; SCALE FOR ASSESSMENT OF NEGATIVE SYMPTOM; SCALE FOR ASSESSMENT OF POSITIVE SYMPTOM; SCORING SYSTEM; SYMPTOM; THOUGHT DISORDER; TREATMENT DURATION; ADOLESCENT; COMPARATIVE STUDY; FEMALE; PSYCHOSES, SUBSTANCE-INDUCED; SYMPTOM ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AMPHETAMINE; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHOSES, SUBSTANCE-INDUCED; QUINOLONES; RISPERIDONE; SYMPTOM ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890933304     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2013.861843     Document Type: Article

References (21)

1. McCann UD, Ricaurte GA. Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosc Biobehav Rev 2004; 27:821-826.
2. Mack AH, Frances RJ, Miller SI. Clinical textbook of addictive disorders. 3rd ed. New York: The Guilford Press; 2005. p. 207. ISBN 1-59385-174.
3. Logan BK. Methamphetamine - effects on human performance and behavior. Forensic Sci Rev 2002;14:134-151.
4. Brecht ML, O'Brien A, von Mayrhauser C, Anglin MD. Methamphetamine use behaviors and gender differences. Addict Behav 2004;29:89-106.
5. Cretzmeyer M, Sarrazin MV, Huber DL, Block RI, Hall JA. Treatment of methamphetamine abuse: research findings and clinical directions. J Subst Abuse Treat 2003;24:267-277.
6. Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction 2009;104:1085-1099.
7. McCann UD, Ricature GA. Amphetamine (or Amphetamine-like)- related disorders. In: Sadock BJ, Sadock VA, Ruiz P. eds. Kaplan and Sadock's comprehensive textbook of psychiatry. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2009:1288-1296.
8. Leamon MH, Gibson DR, Canning RD, Benjamin L. Hospitalization of patients with cocaine and amphetamine use disorders from a psychiatric emergency service. Psychiatric Services 2002;53:1461-1466.
9. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson RA. Psychopathology in methamphetaminedependent adults 3 years after treatment. Drug Alcohol Rev 2010;29:12-20.
10. McKetin R, McLaren J, Lubman DI, Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction. 2006;101:1473-1478.
11. Sommers I, Baskin D, Baskin-Sommers A. Methamphetamine use among young adults: health and social consequences. Addict Behav 2006;31:1469-1476.
12. Leamon MH, Flower K, Salo RE, Nordahl TE, Kranzler HR, Galloway GP. Methamphetamine and paranoia: the methamphetamine experience questionnaire. Am J Addictions 2010;19: 155-168.
13. Caton CLM, Hasin DS, Shrout PE, Drake RE, Dominguez B, First MB, Samet S, Schanzer B. Stability of early-phase primary psychotic disorders with concurrent substance use and substanceinduced psychosis. Br J Psychiat 2007;190:105-111.
14. Bramness JG, Gundersen ØH, Guterstam J, Rognli EB, Konstenius M, Løberg E-M, Medhus S, et al. Amphetamine-induced psychosis - a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiat 2012;12:221.
15. Zarghami M. Methamphetamine has changed the profile of patients utilizing psychiatric, emergency services in Iran. Iran J Psychiat Behav Sci 2011;5:1-5.
16. McKetin R, McLaren J, Lubman DI, Hides L. Hostility among methamphetamine users experience psychotic symptoms. Am J Addict 2008;17:235-240.
17. Leelahanaj T, Kongsakon R, Netrakom P. A 4-week, doubleblind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. J Med Assoc Thai 2005;88: S43-S52.
18. Marder SR, Hurford IM, Van Kammen DP. Second generation antipsychotics. In: Sadock BJ, Sadock VA, Ruiz P. eds. Kaplan and Sadock's comprehensive textbook of psychiatry. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2009:3214-3218.
19. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV-TR Axis I disorders, Research Version, Patient Edition. (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; 2002.
20. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiat 1982;39:784-788.
21. Andreasen N. Scale for the assessment of positive symptoms. Iowa City, IA: University of Iowa; 1984.